Including brain volume loss as an additional criterion in the 'no evidence of disease activity' (NEDA) measure of relapsing–remitting multiple sclerosis progression could help to assess neurodegeneration as well as inflammation. NEDA-3, the current form of the measure, is defined as the absence of disease activity on MRI, relapses and the progression of disability. Ludwig Kappos et al. updated the measure to NEDA-4 by adding brain volume loss, and applied it to analyse pooled data from two trials of fingolimod. NEDA-4 reduced the proportion of participants who achieved NEDA, but remained sensitive to the benefits of treatment detected with NEDA-3.
References
Kappos, L. et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing–remitting multiple sclerosis. Mult. Scler. http://dx.doi.org/10.1177/1352458515616701
Rights and permissions
About this article
Cite this article
Fyfe, I. Brain volume loss strengthens disease measure. Nat Rev Neurol 12, 2 (2016). https://doi.org/10.1038/nrneurol.2015.245
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2015.245
